

OCRA WOMAN TO WOMAN PEER SUPPORT PROGRAM



A cancer diagnosis can be an overwhelming experience. Woman to Woman is a peer-to-peer support program for patients diagnosed with gynecologic cancers. Cancer patients are paired with trained peer mentors, who provide one-on-one emotional support and shared experiences.

Woman to Woman also promotes education and self-advocacy for those in treatment. From the moment of diagnosis through the end of treatment, Woman to Woman peer mentors have helped hundreds of patients cope with a gynecologic cancer diagnosis.

Recently, we expanded Woman to Woman to include a National Program made up of mentors from across the country who are willing to connect with those who may not have an available local program. Matches made through the National Program connect via phone or email.

All services are offered free of charge to participants.

HERE TO HELP

Woman to Woman mentors are here to help—to listen, to discuss concerns, provide support, and sometimes, just hold your hand.

These mentors give hope, along with the special insights that can only come from someone with their own personal gynecologic cancer experience. You will be carefully matched with a mentor that's a good fit for you—your cancer type, age, language and culture, and any other preferences you have, will be taken into account.


HERE FOR YOU

Your Woman to Woman mentor will be with you through the duration of your diagnosis, treatment, and recovery, for as long as you would like to be matched.

Historically, women have met in-person at the hospital, but how, when, and where you connect is up to you. Conversations can take place over the phone or email, too. Woman to Woman also offers participants helpful educational materials on gynecologic cancers.

Interested in finding support, applying to be a mentor, or bringing Woman to Woman to your area?

To learn more, visit www.ocrahope.org/womantowoman or email: womantowoman@ocrahope.org



Woman to Woman is generously supported in part by grants from AstraZeneca, Gail Baird Foundation, Genentech, and GSK.